KWM
AYTU icon

Kanen Wealth Management’s AYTU BioPharma AYTU Stock Holding History

Kanen Wealth Management’s Portfolio AYTU Stock Details AYTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-573,358
Closed -$1.25M – 31
2025
Q2 		$1.25M Buy
+573,358
New +$891K 0.48% 20

Other funds holding AYTU

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Kanen Wealth Management's AYTU Position: Q3 2025 in Review

Kanen Wealth Management sold out of AYTU BioPharma (AYTU) in Q3 2025, closing a stake of 573,358 shares — an estimated $1.25M sold.

Kanen Wealth Management first reported a position in AYTU in Q2 2025 and held it in 1 quarter. The position peaked at $1.25M in Q2 2025. 33 funds tracked by Wall St. Rank hold AYTU as of Q3 2025.

  • Kanen Wealth Management reported no remaining AYTU BioPharma position as of Q3 2025 after selling out during the quarter.
  • Kanen Wealth Management sold 573,358 AYTU BioPharma shares in Q3 2025, an estimated $1.25M.
  • Kanen Wealth Management first reported a position in AYTU BioPharma in Q2 2025 and held it in 1 quarter.
  • Kanen Wealth Management's AYTU BioPharma position peaked at $1.25M in Q2 2025.
  • 33 funds tracked by Wall St. Rank held AYTU BioPharma as of Q3 2025.

Based on Kanen Wealth Management's 13F filing for Q3 2025, filed 14 Nov 2025.